Uncategorized
Direct-to-consumer genetic tests for AMD risk assessment far from reliable
LONDON — Direct-to-consumer genetic tests for age-related macular degeneration, currently widely available via the Internet, cannot provide reliable risk assessment and are not suitable for clinical application, according to one speaker at the Euretina Congress. Caroline C. M. Klaver, MD, PhD, tried several of the direct-to-consumer (DTC) tests available for Europeans on herself, a colleague and one of her doctoral students, collected and sent biosamples according to the accompanying instructions for each test, and obtained predicted risk results, which were inconsistent and contradictory.